IMR Press / CEOG / Volume 31 / Issue 4 / pii/2004079

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Fetal tachycardia: Is digitalis still the first-line therapy?

Show Less
1 1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokrateion General Hospital (Greece)
2 Department of Neonatology, Hippokrateion General Hospital (Greece)
3 2nd Propedeutical Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokrateion General Hospital, Thesssaloniki (Greece)
Clin. Exp. Obstet. Gynecol. 2004, 31(4), 293–295;
Published: 10 December 2004
Abstract

Medical treatment of fetal tachycardias has substantially improved neonatal outcome over the past years. Digitalis has been often used as first-line therapy in these cases, and more recently the use of several newer agents have been reported. We present four cases of fetal tachycardia with a favorable neonatal outcome after successful treatment with digitalis. Rapid transplacental digitalization appears to be an effective and reliable treatment option for fetal tachycardia, particularly in non-hydropic fetuses. In hydropic fetuses, however, digitalis alone appears to be less effective and administration of a second drug is usually needed.

Keywords
Fetal tachycardia
Digitalis
Digoxin
Share
Back to top